Semarion is a spin-out company from Cambridge University with a mission to accelerate the pace of drug discovery. We are revolutionising adherent cell screening to produce better drug data, faster. Our proprietary SemaCyte® microcarrier platform leverages novel materials physics to introduce flexibility, miniaturisation, and multiplexing into existing drug discovery workflows. Our assaying microcarriers function as magnetically steerable, ultra-miniaturized wells which carry small colonies of adherent cells into suspension. These materials are compatible with typical research tools and equipment, where they accelerate workflows and enable novel research methodologies.